| 產品編號 | bs-1468R-PE-Cy5 |
| 英文名稱1 | Rabbit Anti-MDR1/P Glycoprotein/PE-Cy5 Conjugated antibody |
| 中文名稱 | PE-Cy5標記的多藥耐藥蛋白/P-糖蛋白抗體(C端) |
| 別 名 | ABC20; ABCB1; ATP binding cassette, sub family B (MDR/TAP), member 1; ATP-binding cassette sub-family B member 1; CD243; CLCS; Colchicin sensitivity; Doxorubicin resistance; GP170; MDR1; MDR1_HUMAN; Multidrug resistance 1; Multidrug resistance protein 1; P glycoprotein 1; P gp; P-glycoprotein 1; PGY1. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 細胞生物 免疫學 信號轉導 細胞凋亡 轉錄調節(jié)因子 糖蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse, Rat, (predicted: Human, ) |
| 產品應用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 141kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MDR1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: P Glycoprotein, the product of the MDR1 gene, is expressed in distinct non-malignant cells, typically cells with secretory and excretory functions. It is assumed to function as an ATP-dependent drug efflux pump with broad substrate specificity. The highest expression of P Glycoprotein has been observed in kidney (proximal tubules), liver (bile canaliculi), adrenal gland and intestine, suggesting that the primary role of P Glycoprotein is in the normal secretion of physiological metabolites and ingested chemicals into bile, urine and the lumen of the intestinal tract. Elevated levels of P Glycoprotein have also been reported in multidrug-resistant cell lines and in colon, endometrial, ovarian, and breast tumors, as well as in sarcomas and leukemias / lymphomas. Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells. Subunit: Interacts with PSMB5. Subcellular Location: Cell membrane; Multi-pass membrane protein (By similarity). Tissue Specificity: Expressed in liver, kidney, small intestine and brain. DISEASE: Genetic variations in ABCB1 are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases. Similarity: Belongs to the ABC transporter superfamily. ABCB family. Multidrug resistance exporter (TC 3.A.1.201) subfamily. Contains 2 ABC transmembrane type-1 domains. Contains 2 ABC transporter domains. Database links: Entrez Gene: 5243 Human Entrez Gene: 18669 Mouse Omim: 171050 Human SwissProt: P08183 Human SwissProt: P06795 Mouse Unigene: 489033 Human Unigene: 144554 Rat Unigene: 154810 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 信號傳導（Signaling Intermediates） |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
